Marshall Wace’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,442,472
| Closed | -$27.7M | – | 3755 |
|
|
2026
Q1 | $27.7M | Buy |
1,442,472
+566,941
| +65% | +$12.3M | 0.03% | 584 |
|
|
2025
Q4 | $19.2M | Buy |
+875,531
| New | +$15.8M | 0.02% | 640 |
|
|
2025
Q2 | – | Sell |
-70,399
| Closed | -$1.35M | – | 3176 |
|
|
2025
Q1 | $1.35M | Sell |
70,399
-880,549
| -93% | -$25.8M | ﹤0.01% | 1652 |
|
|
2024
Q4 | $34.3M | Buy |
950,948
+137,354
| +17% | +$4.65M | 0.04% | 381 |
|
|
2024
Q3 | $34.5M | Buy |
813,594
+289,201
| +55% | +$12.3M | 0.04% | 362 |
|
|
2024
Q2 | $21.1M | Sell |
524,393
-2,595,981
| -83% | -$108M | 0.03% | 480 |
|
|
2024
Q1 | $110M | Buy |
3,120,374
+2,768,459
| +787% | +$74.2M | 0.17% | 113 |
|
|
2023
Q4 | $10.4M | Buy |
351,915
+172,875
| +97% | +$3.59M | 0.02% | 680 |
|
|
2023
Q3 | $3.72M | Sell |
179,040
-478,121
| -73% | -$13.1M | 0.01% | 982 |
|
|
2023
Q2 | $16.1M | Buy |
+657,161
| New | +$21.1M | 0.03% | 555 |
|
|
2023
Q1 | – | Sell |
-881,307
| Closed | -$39.6M | – | 3106 |
|
|
2022
Q4 | $39.6M | Buy |
+881,307
| New | +$39.9M | 0.09% | 247 |
|
|
2022
Q2 | – | Sell |
-24,703
| Closed | -$2.87M | – | 3845 |
|
|
2022
Q1 | $2.87M | Sell |
24,703
-55,673
| -69% | -$6.5M | 0.01% | 1821 |
|
|
2021
Q4 | $12.1M | Buy |
80,376
+64,572
| +409% | +$8.72M | 0.02% | 733 |
|
|
2021
Q3 | $1.89M | Buy |
+15,804
| New | +$1.74M | 0.01% | 1606 |
|
|
2021
Q2 | – | Sell |
-4,795
| Closed | -$424K | – | 3095 |
|
|
2021
Q1 | $424K | Buy |
4,795
+646
| +16% | +$60K | ﹤0.01% | 2005 |
|
|
2020
Q4 | $397K | Sell |
4,149
-9,184
| -69% | -$946K | ﹤0.01% | 1575 |
|
|
2020
Q3 | $1.51M | Buy |
13,333
+3,443
| +35% | +$362K | 0.01% | 888 |
|
|
2020
Q2 | $978K | Buy |
+9,890
| New | +$789K | 0.01% | 1001 |
|
|
2020
Q1 | – | Sell |
-5,140
| Closed | -$306K | – | 2061 |
|
|
2019
Q4 | $306K | Sell |
5,140
-3,433
| -40% | -$212K | ﹤0.01% | 1274 |
|
|
2019
Q3 | $506K | Buy |
8,573
+2,839
| +50% | +$181K | ﹤0.01% | 1106 |
|
|
2019
Q2 | $370K | Buy |
+5,734
| New | +$370K | ﹤0.01% | 1138 |
|
|
2019
Q1 | – | Sell |
-14,699
| Closed | -$558K | – | 2059 |
|
|
2018
Q4 | $558K | Buy |
+14,699
| New | +$519K | 0.01% | 1064 |
|
Other funds holding TNDM
Marshall Wace's TNDM Position: Q2 2026 in Review
Marshall Wace sold out of Tandem Diabetes Care (TNDM) in Q2 2026, closing a stake of 1,442,472 shares — an estimated $27.7M sold.
Marshall Wace first reported a position in TNDM in Q4 2018 and held it in 22 quarters. The position peaked at $110M in Q1 2024. 274 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.
- Marshall Wace reported no remaining Tandem Diabetes Care position as of Q2 2026 after selling out during the quarter.
- Marshall Wace sold 1,442,472 Tandem Diabetes Care shares in Q2 2026, an estimated $27.7M.
- Marshall Wace first reported a position in Tandem Diabetes Care in Q4 2018 and held it in 22 quarters.
- Marshall Wace's Tandem Diabetes Care position peaked at $110M in Q1 2024.
- 274 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.